Ipilimumab Biosimilar - Anti-CTLA-4 mAb - Research Grade
Source
DrugBank DB06186
Species
Human
Molecular weight
148kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Ipilimumab,Ipilimumab,CTLA-4,anti-CTLA-4
Reference
PX-TA1021
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1, kappa
Description of Ipilimumab Biosimilar - Anti-CTLA-4 mAb - Research Grade
General information about Ipilimumab
Ipilimumab is a monoclonal antibody used in the treatment of melanoma. It is an antibody that inhibits the CTLA-4 checkpoint of T lymphocytes, a checkpoint that certain cancers activate to decrease the efficiency of the lymphocyte. Ipilimumab is a human monoclonal antibody of the IgG1 type directed against the CTLA-4 protein (Cytotoxic T-Lymphocyte Antigen 4). The inhibition of this receptor present on the T lymphocytes results in the activation of the T lymphocyte. This product is for research use only.
Reviews
There are no reviews yet.